Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ.

Blood Adv. 2019 Oct 8;3(19):2812-2815. doi: 10.1182/bloodadvances.2019000600. No abstract available.

2.

Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines.

Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ, Beatty GL.

Cell Mol Gastroenterol Hepatol. 2019 Aug 6. pii: S2352-345X(19)30096-7. doi: 10.1016/j.jcmgh.2019.07.008. [Epub ahead of print] No abstract available.

3.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW.

Blood. 2019 Jul 4;134(1):44-58. doi: 10.1182/blood.2018885863. Epub 2019 May 10.

PMID:
31076448
4.

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.

Salas-Mckee J, Kong W, Gladney WL, Jadlowsky JK, Plesa G, Davis MM, Fraietta JA.

Hum Vaccin Immunother. 2019;15(5):1126-1132. doi: 10.1080/21645515.2019.1571893. Epub 2019 Apr 2.

PMID:
30735463
5.

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.

Feins S, Kong W, Williams EF, Milone MC, Fraietta JA.

Am J Hematol. 2019 May;94(S1):S3-S9. doi: 10.1002/ajh.25418. Epub 2019 Feb 18. Review.

PMID:
30680780
6.

CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, DeGaramo DA, Levine BL, Fraietta JA.

Front Immunol. 2018 Dec 3;9:2740. doi: 10.3389/fimmu.2018.02740. eCollection 2018. Review.

7.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

8.

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Zhang C, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC.

Cancer Immunol Res. 2018 Sep;6(9):1100-1109. doi: 10.1158/2326-6066.CIR-17-0405. Epub 2018 Jul 20.

9.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.

Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ.

Nature. 2018 Jun;558(7709):307-312. doi: 10.1038/s41586-018-0178-z. Epub 2018 May 30.

10.

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH.

Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8.

11.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ.

Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.

12.

Biomarkers in chimeric antigen receptor T-cell therapy.

Kong W, Lacey SF, Melenhorst JJ, Fraietta JA.

Biomark Med. 2018 May;12(5):415-418. doi: 10.2217/bmm-2018-0054. Epub 2018 Apr 26. No abstract available.

13.

Toward precision manufacturing of immunogene T-cell therapies.

Xu J, Melenhorst JJ, Fraietta JA.

Cytotherapy. 2018 May;20(5):623-638. doi: 10.1016/j.jcyt.2017.12.007. Epub 2018 Apr 10. Review.

PMID:
29653875
14.

The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8+ T Cells via SHIP-1.

Hope JL, Stairiker CJ, Spantidea PI, Gracias DT, Carey AJ, Fike AJ, van Meurs M, Brouwers-Haspels I, Rijsbergen LC, Fraietta JA, Mueller YM, Klop RC, Stelekati E, Wherry EJ, Erkeland SJ, Katsikis PD.

Front Immunol. 2017 Dec 6;8:1696. doi: 10.3389/fimmu.2017.01696. eCollection 2017.

15.

Ibrutinib treatment improves T cell number and function in CLL patients.

Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC.

J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

16.

Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

Fraietta JA, Schwab RD, Maus MV.

Semin Oncol. 2016 Apr;43(2):291-9. doi: 10.1053/j.seminoncol.2016.02.006. Epub 2016 Feb 9. Review.

17.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Kawalekar OU, O' Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH.

Immunity. 2016 Mar 15;44(3):712. doi: 10.1016/j.immuni.2016.02.023. Epub 2016 Mar 15. No abstract available.

18.

IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.

Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL.

Cancer Discov. 2016 Apr;6(4):400-413. doi: 10.1158/2159-8290.CD-15-1032. Epub 2016 Feb 19.

19.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH.

Immunity. 2016 Feb 16;44(2):380-90. doi: 10.1016/j.immuni.2016.01.021. Erratum in: Immunity. 2016 Mar 15;44(3):712. Snyder, Nathaniel [corrected to Snyder, Nathaniel W]; Blair, Ian [corrected to Blair, Ian A]. Erratum in: Immunity. 2016 Mar 15;44(3):712.

20.

Rapid Evolution of the CD8+ TCR Repertoire in Neonatal Mice.

Carey AJ, Gracias DT, Thayer JL, Boesteanu AC, Kumova OK, Mueller YM, Hope JL, Fraietta JA, van Zessen DB, Katsikis PD.

J Immunol. 2016 Mar 15;196(6):2602-13. doi: 10.4049/jimmunol.1502126. Epub 2016 Feb 12.

21.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.

Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.

22.

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV.

Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.

23.

Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections.

Gracias DT, Boesteanu AC, Fraietta JA, Hope JL, Carey AJ, Mueller YM, Kawalekar OU, Fike AJ, June CH, Katsikis PD.

J Immunol. 2016 Feb 1;196(3):1186-98. doi: 10.4049/jimmunol.1501890. Epub 2016 Jan 6.

24.

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.

Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2015 Feb 18;7(275):275ra22. doi: 10.1126/scitranslmed.aaa4963.

25.

Acute exposure to ZnO nanoparticles induces autophagic immune cell death.

Johnson BM, Fraietta JA, Gracias DT, Hope JL, Stairiker CJ, Patel PR, Mueller YM, McHugh MD, Jablonowski LJ, Wheatley MA, Katsikis PD.

Nanotoxicology. 2015;9(6):737-48. doi: 10.3109/17435390.2014.974709. Epub 2014 Nov 7.

PMID:
25378273
26.

Abasic phosphorothioate oligomers inhibit HIV-1 reverse transcription and block virus transmission across polarized ectocervical organ cultures.

Fraietta JA, Mueller YM, Lozenski KL, Ratner D, Boesteanu AC, Hancock AS, Lackman-Smith C, Zentner IJ, Chaiken IM, Chung S, LeGrice SF, Snyder BA, Mankowski MK, Jones NM, Hope JL, Gupta P, Anderson SH, Wigdahl B, Katsikis PD.

Antimicrob Agents Chemother. 2014 Dec;58(12):7056-71. doi: 10.1128/AAC.02991-14. Epub 2014 Sep 15.

27.

Adoptive immunotherapy for cancer or viruses.

Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH.

Annu Rev Immunol. 2014;32:189-225. doi: 10.1146/annurev-immunol-032713-120136. Epub 2014 Jan 9. Review.

28.

Immunotherapy with chimeric antigen receptors for multiple myeloma.

Garfall AL, Fraietta JA, Maus MV.

Discov Med. 2014 Jan;17(91):37-46. Review.

29.

Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection.

Fraietta JA, Mueller YM, Yang G, Boesteanu AC, Gracias DT, Do DH, Hope JL, Kathuria N, McGettigan SE, Lewis MG, Giavedoni LD, Jacobson JM, Katsikis PD.

PLoS Pathog. 2013;9(10):e1003658. doi: 10.1371/journal.ppat.1003658. Epub 2013 Oct 10.

30.

The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling.

Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, Katsikis PD.

Nat Immunol. 2013 Jun;14(6):593-602. doi: 10.1038/ni.2576. Epub 2013 Apr 21.

31.

Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Fraietta JA, Mueller YM, Do DH, Holmes VM, Howett MK, Lewis MG, Boesteanu AC, Alkan SS, Katsikis PD.

Antimicrob Agents Chemother. 2010 Oct;54(10):4064-73. doi: 10.1128/AAC.00367-10. Epub 2010 Jul 12.

Supplemental Content

Loading ...
Support Center